BACKGROUND: We assessed HIV RNA suppression, resistance, and CD4 T-cell count 12 months postpartum among pregnant women retained in care in an observational cohort study. METHODS: We prospectively followed two groups of HIV-infected pregnant women--with or without tuberculosis--recruited from prenatal clinics in South Africa. Women who received antiretroviral therapy during pregnancy and reported being on therapy 12 months postpartum were included. Serum samples from women with HIV viremia 12 months postpartum were tested for drug resistance. RESULTS: Of 103 women in the study, median age and CD4 T-cell count at enrollment were 29 years [interquartile range (IQR): 26-32] and 317 cells per cubic millimeter (IQR: 218-385), respectively; 43 (42%) had tuberculosis at baseline. During pregnancy, 87% of the women achieved an HIV RNA <400 copies per milliliter compared with 71% at 12 months postpartum (P < 0.001). Factors independently associated with an HIV RNA <400 copies per milliliter at 12 months were age ≥ 30 years, detectable plasma efavirenz concentration, and HIV RNA <400 copies per milliliter while pregnant; there was a trend toward both a detectable viral load and peripartum depression. HIV drug resistance results were available from 25 women, and 12 (48%) had major drug resistance mutations. CD4 T-cell count declined a median of 13 cells per cubic millimeter (IQR: -66 to 140) from delivery to 12 months in women with viremia at 12 months. CONCLUSIONS: Success with maintaining virologic control declined postpartum among HIV-infected women who remained in care and on antiretroviral therapy, and CD4 T-cell count decline and drug resistance were common.
BACKGROUND: We assessed HIV RNA suppression, resistance, and CD4 T-cell count 12 months postpartum among pregnant women retained in care in an observational cohort study. METHODS: We prospectively followed two groups of HIV-infected pregnant women--with or without tuberculosis--recruited from prenatal clinics in South Africa. Women who received antiretroviral therapy during pregnancy and reported being on therapy 12 months postpartum were included. Serum samples from women with HIV viremia 12 months postpartum were tested for drug resistance. RESULTS: Of 103 women in the study, median age and CD4 T-cell count at enrollment were 29 years [interquartile range (IQR): 26-32] and 317 cells per cubic millimeter (IQR: 218-385), respectively; 43 (42%) had tuberculosis at baseline. During pregnancy, 87% of the women achieved an HIV RNA <400 copies per milliliter compared with 71% at 12 months postpartum (P < 0.001). Factors independently associated with an HIV RNA <400 copies per milliliter at 12 months were age ≥ 30 years, detectable plasma efavirenz concentration, and HIV RNA <400 copies per milliliter while pregnant; there was a trend toward both a detectable viral load and peripartum depression. HIV drug resistance results were available from 25 women, and 12 (48%) had major drug resistance mutations. CD4 T-cell count declined a median of 13 cells per cubic millimeter (IQR: -66 to 140) from delivery to 12 months in women with viremia at 12 months. CONCLUSIONS: Success with maintaining virologic control declined postpartum among HIV-infectedwomen who remained in care and on antiretroviral therapy, and CD4 T-cell count decline and drug resistance were common.
Authors: Julie A Denison; Olivier Koole; Sharon Tsui; Joris Menten; Kwasi Torpey; Eric van Praag; Ya Diul Mukadi; Robert Colebunders; Andrew F Auld; Simon Agolory; Jonathan E Kaplan; Modest Mulenga; Gideon P Kwesigabo; Fred Wabwire-Mangen; David R Bangsberg Journal: AIDS Date: 2015-01-28 Impact factor: 4.177
Authors: Francis Yeji; Kerstin Klipstein-Grobusch; Marie-Louise Newell; Lisa R Hirschhorn; Victoria Hosegood; Till Bärnighausen Journal: AIDS Care Date: 2014-07-03
Authors: Kelly E Dooley; Paolo Denti; Neil Martinson; Silvia Cohn; Fildah Mashabela; Jennifer Hoffmann; David W Haas; Jennifer Hull; Regina Msandiwa; Sandra Castel; Lubbe Wiesner; Richard E Chaisson; Helen McIlleron Journal: J Infect Dis Date: 2014-07-31 Impact factor: 5.226
Authors: Annemarie M Wensing; Vincent Calvez; Huldrych F Günthard; Victoria A Johnson; Roger Paredes; Deenan Pillay; Robert W Shafer; Douglas D Richman Journal: Top Antivir Med Date: 2014 Jun-Jul
Authors: Matilda Ngarina; Rebecca Popenoe; Charles Kilewo; Gunnel Biberfeld; Anna Mia Ekstrom Journal: BMC Public Health Date: 2013-05-07 Impact factor: 3.295
Authors: Maria Paximadis; Refilwe N Ngqobe; Richard E Chaisson; Neil A Martinson; Caroline T Tiemessen Journal: Infect Genet Evol Date: 2017-01-06 Impact factor: 3.342
Authors: Landon Myer; Andrew D Redd; Elton Mukonda; Briana A Lynch; Tamsin K Phillips; Anna Eisenberg; Nei-Yuan Hsiao; Adam Capoferri; Alison Zerbe; William Clarke; Maia Lesosky; Autumn Breaud; James McIntyre; Daniel Bruno; Craig Martens; Elaine J Abrams; Steven J Reynolds Journal: Clin Infect Dis Date: 2020-01-16 Impact factor: 9.079
Authors: Emily L Tuthill; Lisa M Butler; Jennifer A Pellowski; Jacqueline M McGrath; Regina M Cusson; Robert K Gable; Jeffrey D Fisher Journal: Public Health Nutr Date: 2017-02-08 Impact factor: 4.022
Authors: Catherine A Koss; Paul Natureeba; Dalsone Kwarisiima; Mike Ogena; Tamara D Clark; Peter Olwoch; Deborah Cohan; Jaffer Okiring; Edwin D Charlebois; Moses R Kamya; Diane V Havlir Journal: J Acquir Immune Defic Syndr Date: 2017-03-01 Impact factor: 3.731
Authors: Oladele Vincent Adeniyi; Anthony Idowu Ajayi; Daniel Ter Goon; Eyitayo Omolara Owolabi; Alfred Eboh; John Lambert Journal: BMC Infect Dis Date: 2018-04-13 Impact factor: 3.090
Authors: Lisa L Abuogi; John M Humphrey; Christian Mpody; Marcel Yotebieng; Pamela M Murnane; Kate Clouse; Lindah Otieno; Craig R Cohen; Kara Wools-Kaloustian Journal: J Virus Erad Date: 2018-11-15